Faculty Information - 福田　洋典

（Last updated : 2024-05-02 14:48:44）

福田　洋典
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Department of Urology

Position Assistant Professor

■ Published papers

1.	Original article	Renal cell carcinoma outcomes in end-stage renal disease: A 40-year study from two Japanese institutions. 2024/01
2.	Original article	Predictive factors and oncological outcomes of pathological T3a upstaging in patients with clinical T1 renal cell carcinoma undergoing partial nephrectomy. 2023/10
3.	Original article	Real-world efficacy and safety of cabozantinib following immune checkpoint inhibitor failure in Japanese patients with advanced renal cell carcinoma. 2023/10
4.	Original article	Association between lung immune prognostic index and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab. 2023/07
5.	Original article	Higher risk of intraoperative bleeding in right-sided renal tumors compared to left-sided tumors in robot-assisted partial nephrectomy. 2023/07
6.	Review article	Impact of sex on prognosis in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors. 2023/07
7.	Case report	Long-time survival of a renal transplant recipient with metastatic mucinous tubular and spindle cell carcinoma: A case report. 2023/05
8.	Original article	Comparison of outcomes between therapeutic combinations based on immune checkpoint inhibitors or tyrosine kinase inhibitor monotherapy for first-line therapy of patients with advanced renal cell carcinoma outside of clinical trials: A real-world retrospective multi-institutional study. 2023/03
9.	Original article	Efficacy of combined pembrolizumab and pelvic radiotherapy for bladder cancer with rectal metastases. 2023/03
10.	Original article	Continuation of immune checkpoint inhibitors for newly developed brain metastasis during immune checkpoint inhibitor treatment for oligoprogressive metastatic renal cell carcinoma. 2023/02
11.	Original article	Impact of body mass index on outcomes in an asian population of advanced renal cell carcinoma and urothelial carcinoma treated with immune checkpoint inhibitors. 2023/02
12.	Original article	Comparison of the impact of immune-related adverse events due to immune checkpoint inhibitor dual combination therapy and immune checkpoint inhibitor plus tyrosine kinase inhibitor combination therapy in patients with advanced renal cell carcinoma. 2023/01
13.	Original article	Analyses of operative time according to procedure phases during robot-assisted laparoscopic partial nephrectomy using the iPhone application “My Intuitives” 2022/11
14.	Original article	Outcomes of nivolumab monotherapy for previously treated metastatic renal cell carcinoma: a real-world multi-institution data with a minimum of 2 years of follow-up. 2022/07/08
15.	Original article	Efficacy and Safety of Immunotherapy-Based Combinations as First-Line Therapy of Metastatic Renal Cell Carcinoma in Patients Who Do Not Meet Trial Eligibility Criteria 2022/07/05
16.	Original article	Role of fractalkine-CX3CR1 axis in acute rejection of mouse heart allografts subjected to ischemia reperfusion injury 2022/02/01
17.	Original article	Predictive impact of early changes in serum C-reactive protein levels in nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma. 2022/02
18.	Original article	Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma. 2022/01
19.	Original article	Assessment of Feasibility of Robot-assistted Radical Cystectomy in Patients With Advanced Bladder Cancer Treated With Maintenance Hemodialysis Therapy 2022
20.	Original article	Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinoma. 2021/12
21.	Original article	Hypopituitarism in patients with metastatic renal cell carcinoma treated with ipilimumab and nivolumab combination therapy. 2021/12
22.	Original article	Comparable survival outcome between acquired cystic disease associated renal cell carcinoma and clear cell carcinoma in patients with end-stage renal disease: a multi-institutional central pathology study. 2021/10
23.	Original article	Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. 2021/10
24.	Original article	Albumin-to-alkaline phosphatase ratio as a novel prognostic marker of nivolumab monotherapy for previously treated metastatic renal cell carcinoma. 2021/09
25.	Original article	Prognostic impact of trial-eligibility criteria in patients with metastatic renal cell carcinoma 2021/08
26.	Original article	Prognostic impact of early treatment interruption of nivolumab plus ipilimumab due to immune-related adverse events as first-line therapy for metastatic renal cell carcinoma: A multi-institution retrospective study. 2021/07
27.	Original article	Outcome of advanced renal cell carcinoma arising in end-stage renal disease: comparison with sporadic renal cell carcinoma. 2021/06
28.	Original article	Assessing improvements in metastatic renal cell carcinoma systemic treatments from the pre-cytokine to the immune checkpoint inhibitor eras: a retrospective analysis of real-world data. 2021/05
29.	Original article	Impact of sarcopenia on post-operative outcomes following nephrectomy and tumor thrombectomy for renal cell carcinoma with inferior vena cava thrombus. 2021/04
30.	Original article	Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma. 2021/04
31.	Original article	Predictive role of γ‑glutamyltransferase in patients receiving nivolumab therapy for metastatic renal cell carcinoma. 2021/03
32.	Original article	The controlling nutritional status CONUT score in patients with advanced bladder cancer after radical cystectomy. 2021/03
33.	Original article	Efficacy of nivolumab versus molecular-targeted therapy as second-line therapy for metastatic renal cell carcinoma: Real-world data from two Japanese institutions. 2021/01
34.	Original article	Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era. 2021/01
35.	Original article	Genetic and epigenetic profiling indicates the proximal tubule origin of renal cancers in end‐stage renal disease. 2020/11
36.	Case report	Total nephroureterocystectomy and urethrectomy due to urothelial carcinoma associated with the BK polyomavirus infection after kidney transplantation: a case report with literature review. 2020/11
37.	Original article	Nivolumab treatment beyond progression for metastatic renal cell carcinoma: New role of metastasectomy in the immune checkpoint inhibitor era? 2020/08
38.	Original article	The de ritis (aspartate transaminase/alanine transaminase) ratio as a prognosticator in patients with end-stage renal disease-associated renal cell carcinoma. 2020/06
39.	Original article	Efficacy of axitinib after nivolumab failure in metastatic renal cell carcinoma. 2020/05
40.	Original article	Predictive factors for recurrence after complete metastasectomy in patients with metastatic renal cell carcinoma in the targeted therapy era. 2020/05
41.	Original article	Predictive factors for recurrence after partial nephrectomy for clinical T1 renal cell carcinoma: a retrospective study of 1227 cases from a single institution. 2020/05
42.	Original article	Predictive impact of an early change in serum C-reactive protein levels in nivolumab therapy for metastatic renal cell carcinoma. 2020/05
43.	Original article	Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma. 2020/04
44.	Original article	Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma. 2019/08
45.	Original article	Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. 2019/06
46.	Original article	Efficacy of axitinib in patients with metastatic renal cell carcinoma refractory to nivolumab therapy. 2019/06
47.	Original article	Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma. 2019/04
48.	Original article	Prognostic markers for refined stratification of IMDC intermediate-risk metastatic clear cell renal cell carcinoma treated with first-line tyrosine kinase inhibitor therapy. 2019/04
49.	Original article	A novel partner of TFE3 in the Xp11 translocation renal cell carcinoma: clinicopathological analyses and detection of EWSR1-TFE3 fusion. 2019/03
Display 5 items
Display all(49)

■ Academic conference presentation

1.	Impact of gender on the efficacy of immune checkpoint inhibitor therapy in renal cell carcinoma. 2024/04/27
2.	Antibiotic and proton pump inhibitor use and survival of patients receiving immune checkpoint inhibitor combination therapy for advanced renal cell carcinoma. 2024/04/26
3.	BRCA mutation-positive prostate cancer at our hospital initial experience with olaparib in BRCA mutation-positive prostate cancer. 2024/04/26
4.	Efficiency of IO-IO combination therapy and IO-TKI combination therapy for renal cell carcinoma with inferior vena cava tumor thrombus. 2024/04/26
5.	Impact of steroids for immune-related adverse events in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitor combination therapy. 2024/04/26
6.	Outcome comparison of IO-IO versus IO-TKI combination therapy for patients with advanced renal cell carcinoma. 2024/04/26
7.	Primary renal tumor response in patients treated with first-line systemic therapy for advanced renal cell carcinoma. 2024/04/26
8.	Utility of whole-body MRI (DWIBS) in treatment decision-making for M0CRPC: A case series study. 2024/04/26
9.	Comparison of Perioperative Outcomes between Robot-Assisted Laparoscopic Radical Nephroureterectomy and Laparoscopic Radical Nephroureterectomy. 2024/04/25
10.	Comparison of surgical outcomes between robot-assisted and conventional laparoscopic adrenalectomy at Tokyo Women's Medical University Hospital. 2024/04/25
11.	Comparison of the impacts of immune-related adverse events on the prognosis of patients with advanced renal cell carcinoma between patients treated with IO-IO and IO-TKI combination therapy.. 2023/04/29
12.	Outcome change in patients with advanced renal celcarcinoma outside of clinicalal trials from the tyrosine-kinase inhibitor era to the immune checkpoint inhibitor era. 2023/04/29
13.	Prognostic factors for recurrence after robot-assisted laparoscopic partial nephrectomy： Real-world data from Japanese single high-volume center. 2023/04/29
14.	Validation of predictive model for new baseline renal function after radical nephrectomy or robot-assisted partial nephrectomy in Japanese patients. 2023/04/29
15.	Initial experiences of robot-assisted adrenalectomy. 2023/04/22
16.	Medication states of up-front ARAT treatment for mHSPC in real-world practice. 2023/04/21
17.	Prognostic factors for recurrence after robot-assisted laparoscopic partial nephrectomy: Real-world data from Japanese single high-volume center. 2023/04/21
18.	Renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion (Xp11.2 RCC). A clinicopathological study of 10 Japanese cases. 2023/04/21
19.	CODEX multiplex immune-staining Identifies novel spatial indexes for antibody-mediated rejection diagnosis. 2023/04/20
20.	Higher risk of intraoperative bleeding in right-sided renal tumors compared to left-sided tumors in robot-assisted partial nephrectomy. 2023/04/20
21.	Outcome in patients with advanced renal cell carcinoma treated with immunotherapy vs. tyrosine kinase inhibitor based on the status of chronic kidney disease. 2023/04/20
22.	Association between immune adverse events and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab. 2022/05/13
23.	Effects of first-line immune checkpoint inhibitors in patients with metastatic renal cell carcinoma not meeting trial eligibility criteria. 2022/05/13
24.	Potential survival benefit of deferred nephrectomy in patients treated with nivolumab plus ipilimumab for metastatic renal cell carcinoma. 2022/05/13
25.	Predictive impact of early changes in serum c-reactive protein levels in nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma. 2022/05/13
26.	Association between controlling nutritional status（CONUT）score and outcomes after radical cystectomy for advanced bladder cancer. 2020/12/23
27.	Association between early tumor response and survival in metastatic renal cell carcinoma treated with nivolumab. 2020/12/23
28.	Comparison of efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma. 2020/12/23
29.	The predictive impact of presurgical sarcopenia on patient survival in patients with renal cell carcinoma with inferior vena cava tumor thrombus. 2020/12/23
30.	Retroperitoneal approach is better quality of recovery than transperitoneal approach after robot-assisted partial nephrectomy. 2020/12/22
31.	Cancer-associated fibroblast recruited a specific subset of myeloidderived suppressor cells to pancreatic cancer tissue. 2020/10/01
32.	Genetic and epigenetic profiling reveals the proximal tubule origin of renal cancers in end-stage renal disease. 2020/10/01
33.	Comparisons of surgical outcomes between transperitoneal and retroperitoneal　approaches in robot-assisted laparoscopic partial nephrectomy for lateral renal tumors: A propensity score-matched comparative analysis. 2020/07/17
34.	Detection of a peritumoral pseudocapsule in patients with renal cell carcinoma undergoingrobot-assisted partial nephrectomy, using enhanced CT. 2020/07/17
35.	Predictive factors for recurrence after complete metastasectomy in patients with metastaticrenal cell carcinoma in the targeted therapy era. 2020/07/17
36.	Usefulness of robot-assisted laparoscopic partial nephrectomy using trifecta criteria. 2020/07/17
37.	The role of pancreatic cancer associated fibroblasts to construct immune suppressive microenvironment. 2019/09/26
38.	Fractalkine is crucial in ischemia reperfusion injury related to acute rejection in an allogeneic heart transplantation model. 2019/06/02
39.	Effect of changes in skeletal muscle mass on oncological outcomes during first-line sunitinib herapy for metastatic renal cell carcinoma. 2019/05/04
40.	Long-term follow-up of renal function and development of chronic kidney disease after partial nephrectomy. 2019/05/04
41.	Association of immune-related adverse events with prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. 2019/05/03
42.	The clinical benefit of metastasectomy in renal cell carcinoma in the ERA of targeted molecular therapy. 2014/09/06
43.	Limited benefit of targeted therapies on ivc thrombus in renal cell carcinoma. 2014/05/19
44.	Impact Of Preoperative C-Reactive Protein On Survival Of Patients On Chronic Hemodialysis Undergoing Nephrectomy For Renal Cell Carcinoma 2013/08/31
45.	The Clinical Benefit of Targeted Therapies On IVC Thrombus Of Renal Cell Carcinoma 2013/08/31
Display 5 items
Display all(45)

■ Research areas

Urology (Key Word：Urology)

■ Education

2015/04～2019/03

〔Doctoral course〕 Urology, Graduate School, Division of Medical Sciences, Tokyo Women's Medical University, Completed, PhD